30 July 2020 | News
Ritucad™ is the second biosimilar in a series of biosimilar products planned by the organization this year
Ahmedabad based Cadila Pharmaceuticals Limited recently announced the launch of biosimilar Rituximab for India market. Biosimilar Rituximab is used for treatment of blood cancer and rheumatoid arthritis, and will be launched under the brand name Ritucad™.
Ritucad™ is used in the treatment of Non-Hodgkin’s lymphoma (a type of blood related cancer). Every year there are more than 28,000 new cases of Lymphoma in India. Cadila has been committed towards providing high quality and affordable care for the patients.
Ritucad™ is the second biosimilar in a series of biosimilar products planned by the organization this year and will be made available in a single dose vial of two strengths, 100 mg and 500mg.
Cadila Pharmaceuticals Ltd is working towards strengthening its biosimilar portfolio and is investing into launching more biosimilar products in the future.
The pharma giant has recently launched Bevasizumab biosimilar which is a humanized monoclonal antibody, recommended in multiple indications under the brand name Bevaro™.